166 related articles for article (PubMed ID: 29468559)
1. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
Liebl A; Mohan V; Yang W; Strojek K; Linjawi S
Drugs R D; 2018 Mar; 18(1):27-39. PubMed ID: 29468559
[TBL] [Abstract][Full Text] [Related]
2. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
Liebl A; Prusty V; Valensi P; Kawamori R; Christiansen JS; Palmer AJ; Balschmidt P; Ligthelm R; Mohan V
Drugs; 2012 Jul; 72(11):1495-520. PubMed ID: 22818015
[TBL] [Abstract][Full Text] [Related]
3. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
4. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
5. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
7. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
[TBL] [Abstract][Full Text] [Related]
8. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
9. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
11. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
13. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
Balaji V; Balaji MS; Alexander C; Srinivasan A; Suganthi SR; Thiyagarajah A; Seshiah V
Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
[TBL] [Abstract][Full Text] [Related]
14. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
[TBL] [Abstract][Full Text] [Related]
16. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
17. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]